Mount Sinai Medical Center (MSMC) announced the results of a clinical trial for certain ovarian cancer treatments led by Dr. Brian Slomovitz, according to a press release.
The trial, sponsored by the GOG Foundation, investigated treatment options for women suffering from low-grade serous ovarian cancer (LGSOC). Afflicted patients were placed on a regimen of ribociclib and letrozole. The response rate was approximately 23%, the progression-free survival rate was 19.1 months and the response duration was also 19.1 months. Slomovitz presented the results at the Society of Gynecologic Oncology's "2023 Annual Meeting on Women's Cancer" in Tampa, Florida.
"These results are promising," Slomovitz said. "Women with this disease have limited treatment options. The progression-free survival and duration of response are both six months greater than what we have observed with the current standard treatments."
Sixty-four percent of patients saw a reduction in target tumor size. According to Slomovitz, the trial's next steps will be to compare the ribociclib and letrozole treatment to current therapies in a head-to-head assessment.
"Hopefully this work can lead to an FDA approval for this combination," he said.
"Mount Sinai Medical Center is excited about this promising advancement for gynecologic cancer patients dealing with rare tumors," the article reads. "This is yet another opportunity to help transform the standard of care in gynecologic oncology."
Ovarian cancer is the eighth leading cause of cancer-related death among women in the world, and LGSOC accounts for 5-10% of all serous carcinomas of the ovary. LGSOC is a rare subtype of ovarian cancer that is typically found in younger women and may result from a non-invasive precursor disease, such as a serious borderline tumor. Approximately 80% of women with LGSOC experience disease recurrence after primary therapy. Traditional treatment options such as chemotherapy, hormonal therapies and biologic targeted therapies have limited clinical efficacy and short response durations.
